Developmental Angiogenesis

Research output: Contribution to journalEditorial

Abstract

Developmental angiogenesis is the beautiful process through which the embryo’s complex pattern of blood vessels throughout the forming body, organs and tissues is established and maintained ([1] ; [2] see Front Cover image). Blood vessels are essential for the normal development of the embryo and angiogenesis, where new vessels form from existing networks through proliferation and migration of endothelial cells to form new vessels. Moreover, the cardiovascular system is one of the first functioning tissues in the human embryo – with a beating heart and rudimentary vascular system by the 4th week of development [3] ; [4]. Indeed, vascular malformations or the failure of normal vessel formation or the failure of the transition from the embryonic to the adult vessel networks can result in damage to the embryo [5]. For example, inhibition of angiogenesis through teratogens such as thalidomide can cause birth defects [5] ; [6], in addition, misregulation of signaling molecules important for normal angiogenesis can also result in malformations, such as limb and brain defects [7]. The importance of the vascular system in embryonic development is further underlined by the large number of signaling molecules that when mutated to cause a loss-of-function in mouse embryos result in embryonic lethality due to failure of vascular development [8] ; [9].
Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalReproductive Toxicology
Volume70
Early online date9 Jun 2017
DOIs
Publication statusPublished - Jun 2017

Fingerprint

Blood vessels
Blood Vessels
Tissue
Teratogens
Cardiovascular system
Embryonic Structures
Defects
Molecules
Thalidomide
Endothelial cells
Brain
Embryonic Development
Vascular Malformations
Cardiovascular System
Extremities
Endothelial Cells

Keywords

  • Embryonic vascular development
  • Drug safety
  • Thalidomide
  • Human embryo
  • Vertebrate embryos
  • Angiogenesis assays
  • ToxCast
  • Drug screens

Cite this

Developmental Angiogenesis. / Vargesson, Neil.

In: Reproductive Toxicology, Vol. 70, 06.2017, p. 1-2.

Research output: Contribution to journalEditorial

@article{a3098f31617a4d9c8cc87427ac52881a,
title = "Developmental Angiogenesis",
abstract = "Developmental angiogenesis is the beautiful process through which the embryo’s complex pattern of blood vessels throughout the forming body, organs and tissues is established and maintained ([1] ; [2] see Front Cover image). Blood vessels are essential for the normal development of the embryo and angiogenesis, where new vessels form from existing networks through proliferation and migration of endothelial cells to form new vessels. Moreover, the cardiovascular system is one of the first functioning tissues in the human embryo – with a beating heart and rudimentary vascular system by the 4th week of development [3] ; [4]. Indeed, vascular malformations or the failure of normal vessel formation or the failure of the transition from the embryonic to the adult vessel networks can result in damage to the embryo [5]. For example, inhibition of angiogenesis through teratogens such as thalidomide can cause birth defects [5] ; [6], in addition, misregulation of signaling molecules important for normal angiogenesis can also result in malformations, such as limb and brain defects [7]. The importance of the vascular system in embryonic development is further underlined by the large number of signaling molecules that when mutated to cause a loss-of-function in mouse embryos result in embryonic lethality due to failure of vascular development [8] ; [9].",
keywords = "Embryonic vascular development, Drug safety, Thalidomide, Human embryo , Vertebrate embryos, Angiogenesis assays, ToxCast, Drug screens",
author = "Neil Vargesson",
note = "This Special Issue could not have happened without the excellent support, help, guidance and confidence shown to me by Tom Knudsen and Cindy Knudsen. I am particularly grateful to Tom Knudsen for this opportunity, it has been a great experience and eye-opening too. I also need to thank the excellent Editorial Staff at Elsevier, particularly Arthi Purushothaman, who was always patient with me, and very helpful, despite my many questions. Finally, I want to thank all the Reviewers of the articles included in this Special Issue for their timely returns of reviews, their help and their support.",
year = "2017",
month = "6",
doi = "10.1016/j.reprotox.2017.05.011",
language = "English",
volume = "70",
pages = "1--2",
journal = "Reproductive Toxicology",
issn = "0890-6238",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Developmental Angiogenesis

AU - Vargesson, Neil

N1 - This Special Issue could not have happened without the excellent support, help, guidance and confidence shown to me by Tom Knudsen and Cindy Knudsen. I am particularly grateful to Tom Knudsen for this opportunity, it has been a great experience and eye-opening too. I also need to thank the excellent Editorial Staff at Elsevier, particularly Arthi Purushothaman, who was always patient with me, and very helpful, despite my many questions. Finally, I want to thank all the Reviewers of the articles included in this Special Issue for their timely returns of reviews, their help and their support.

PY - 2017/6

Y1 - 2017/6

N2 - Developmental angiogenesis is the beautiful process through which the embryo’s complex pattern of blood vessels throughout the forming body, organs and tissues is established and maintained ([1] ; [2] see Front Cover image). Blood vessels are essential for the normal development of the embryo and angiogenesis, where new vessels form from existing networks through proliferation and migration of endothelial cells to form new vessels. Moreover, the cardiovascular system is one of the first functioning tissues in the human embryo – with a beating heart and rudimentary vascular system by the 4th week of development [3] ; [4]. Indeed, vascular malformations or the failure of normal vessel formation or the failure of the transition from the embryonic to the adult vessel networks can result in damage to the embryo [5]. For example, inhibition of angiogenesis through teratogens such as thalidomide can cause birth defects [5] ; [6], in addition, misregulation of signaling molecules important for normal angiogenesis can also result in malformations, such as limb and brain defects [7]. The importance of the vascular system in embryonic development is further underlined by the large number of signaling molecules that when mutated to cause a loss-of-function in mouse embryos result in embryonic lethality due to failure of vascular development [8] ; [9].

AB - Developmental angiogenesis is the beautiful process through which the embryo’s complex pattern of blood vessels throughout the forming body, organs and tissues is established and maintained ([1] ; [2] see Front Cover image). Blood vessels are essential for the normal development of the embryo and angiogenesis, where new vessels form from existing networks through proliferation and migration of endothelial cells to form new vessels. Moreover, the cardiovascular system is one of the first functioning tissues in the human embryo – with a beating heart and rudimentary vascular system by the 4th week of development [3] ; [4]. Indeed, vascular malformations or the failure of normal vessel formation or the failure of the transition from the embryonic to the adult vessel networks can result in damage to the embryo [5]. For example, inhibition of angiogenesis through teratogens such as thalidomide can cause birth defects [5] ; [6], in addition, misregulation of signaling molecules important for normal angiogenesis can also result in malformations, such as limb and brain defects [7]. The importance of the vascular system in embryonic development is further underlined by the large number of signaling molecules that when mutated to cause a loss-of-function in mouse embryos result in embryonic lethality due to failure of vascular development [8] ; [9].

KW - Embryonic vascular development

KW - Drug safety

KW - Thalidomide

KW - Human embryo

KW - Vertebrate embryos

KW - Angiogenesis assays

KW - ToxCast

KW - Drug screens

U2 - 10.1016/j.reprotox.2017.05.011

DO - 10.1016/j.reprotox.2017.05.011

M3 - Editorial

VL - 70

SP - 1

EP - 2

JO - Reproductive Toxicology

JF - Reproductive Toxicology

SN - 0890-6238

ER -